KOREA UNITED PHARM INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24,150 KRW | +0.63% |
|
-3.01% | -10.56% |
| 2023 | Tranche Update on Korea United Pharm Inc.'s Equity Buyback Plan announced on July 15, 2022. | CI |
| 2023 | Tranche Update on Korea United Pharm Inc.'s Equity Buyback Plan announced on July 15, 2022. | CI |
| Sales 2015 | 162B 119M | Sales 2016 * | 177B 130M | Capitalization | 353B 260M |
|---|---|---|---|---|---|
| Net income 2015 * | 19B 13.98M | Net income 2016 * | 18B 13.25M | EV / Sales 2015 | 1.65 x |
| Net cash position 2015 * | 26.3B 19.36M | Net cash position 2016 * | 19.04B 14.01M | EV / Sales 2016 * | 1.89 x |
| P/E ratio 2015 |
12.6
x | P/E ratio 2016 * |
21.6
x | Employees | 665 |
| Yield 2015 |
1.26% | Yield 2016 * |
0.99% | Free-Float | 52.41% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.63% | ||
| 1 week | -3.01% | ||
| Current month | -2.23% | ||
| 1 month | +5.46% | ||
| 3 months | +4.09% | ||
| 6 months | -3.98% | ||
| Current year | -10.56% |
1 week
23 700.00
25 050.00
1 month
22 900.0025 550.00
Current year
21 850.0028 900.00
1 year
21 500.0030 600.00
3 years
20 000.0064 000.00
5 years
10 750.00112 000.00
10 years
9 920.00112 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Won-Ho Kang
CEO | Chief Executive Officer | 47 | - |
Duk-Young Kang
CEO | Chief Executive Officer | 77 | - |
Won-Tae Jeong
BRD | Director/Board Member | 61 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Duk-Young Kang
CEO | Chief Executive Officer | 77 | - |
Gui-Ja Kim
BRD | Director/Board Member | 67 | - |
Won-Ho Kang
CEO | Chief Executive Officer | 47 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-27 | 24,150 | +0.63% | 12 939 |
| 24-05-27 | 24,000 | -2.44% | 47,855 |
| 24-05-24 | 24,600 | -0.20% | 26,020 |
| 24-05-23 | 24,650 | -1.00% | 18,293 |
| 24-05-22 | 24,900 | +0.20% | 17,699 |
End-of-day quote Korea S.E., May 27, 2024
More quotes
KOREA UNITED PHARM. INC. is a Korea-based company engaged in the manufacture and marketing of pharmaceuticals. The Companyâs products include remedies for gastrointestinal system, cardiovascular, hematopoietic system, respiratory system, central nervous system, musculoskeletal system, endocrine and metabolic system, allergy and immune system, as well as anti-infectives, gynecological agents, vitamins, nutrition products, anticancer medicines and others. It also provides active pharmaceutical ingredients (APIs) and various health food products. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-08
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -10.56% | 260M | |
| +16.31% | 42.32B | |
| +16.32% | 21.29B | |
| +19.22% | 15.29B | |
| +18.71% | 14.36B | |
| +52.78% | 12.81B | |
| -0.05% | 6.79B | |
| -12.24% | 6.58B | |
| -8.87% | 5.73B | |
| +11.64% | 5.51B |
- Stock Market
- Equities
- A033270 Stock
